Blood test may predict prostate cancer drug response, avoiding need for biopsy
NCT ID NCT01961843
First seen Jan 03, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tested a new blood test that looks for cancer cells floating in the bloodstream (circulating tumor cells) in 40 men with advanced prostate cancer. The goal was to see if changes in these cells could predict whether the drug abiraterone acetate would work. If successful, this test could help doctors choose the right treatment without needing a painful biopsy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.